NYSEAMERICAN:AIM AIM ImmunoTech Q2 2026 Earnings Report $0.21 -0.01 (-4.51%) Closing price 09/18/2026 04:10 PM EasternExtended Trading$0.21 0.00 (-0.24%) As of 09/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast AIM ImmunoTech EPS ResultsActual EPS-$0.43Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAIM ImmunoTech Revenue ResultsActual Revenue$0.03 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAIM ImmunoTech Announcement DetailsQuarterQ2 2026Date8/7/2026TimeAfter Market ClosesConference Call DateFriday, August 7, 2026Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) AIM ImmunoTech Earnings HeadlinesAIM ImmunoTech Reduces Debt via Equity Exchange AgreementsSeptember 12, 2026 | theglobeandmail.comAIM ImmunoTech Inc.: AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen in Pancreatic Cancer in New CEO Corner VideoSeptember 9, 2026 | finanznachrichten.deTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 19 at 1:00 AM | Porter & Company (Ad)AIM ImmunoTech Advances Ampligen In Phase 2 Pancreatic Cancer StudySeptember 9, 2026 | rttnews.comAIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner VideoSeptember 9, 2026 | globenewswire.comAIM ImmunoTech Secures Europe, U.K. Patent Protection For Ampligen In Long COVID; Shares JumpSeptember 3, 2026 | rttnews.comSee More AIM ImmunoTech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AIM ImmunoTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AIM ImmunoTech and other key companies, straight to your email. Email Address About AIM ImmunoTechAIM ImmunoTech (NYSEAMERICAN:AIM) is a biotechnology company focused on developing and commercializing immunomodulatory therapies for cancer, viral diseases and disorders involving the immune system. The company’s lead product candidate is Ampligen (rintatolimod), an investigational double-stranded RNA therapeutic designed to stimulate immune responses and is being studied in several disease settings. AIM also owns Alferon N Injection, an interferon alfa-n3 product approved in the United States for the treatment of refractory or recurring external genital warts in adults. The company has explored additional applications for its therapies, including potential use against infectious diseases and cancers, through clinical research and collaborations. The company was formerly known as Hemispherx Biopharma Inc. and adopted the name AIM ImmunoTech in 2019. Its corporate headquarters are in Ocala, Florida, and its programs are primarily directed toward the U.S. market while also involving international research and development activities. Thomas K. Equels serves as the company’s president and chief executive officer.View AIM ImmunoTech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
